Evidence map›Paper›PMID 26000476›Full record

ArticleCell2015

A CRISPR View of Cleavage.

Ariel D Weinberger, Michael S Gilmore

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ariel D WeinbergerWyss Institute for Biologically Inspired Engineering, Harvard Medical School, Boston, MA 02115, USA. Electronic address: ariel.weinberger@wyss.harvard.edu.
Michael S GilmoreDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02115, USA; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA.
Harvard University · USMassachusetts Eye and Ear Infirmary · US

Funding

Modeling CRISPR to Preserve AntibioticsR21GM106337 · NIGMS · MASSACHUSETTS EYE AND EAR INFIRMARY · PI GILMORE, MICHAEL S · 2013 to 2014
$405k
The Evolutionary Dynamics of Plasmid Uptake in Pathogenic BacteriaF32AI102520 · NIAID · MASSACHUSETTS EYE AND EAR INFIRMARY · PI WEINBERGER, ARIEL · 2012 to 2014
$141k
NIAID NIH HHS F32AI102520NIGMS NIH HHS GM106337
6 · The paper itself

Abstract

Seminal studies showed that CRISPR-Cas systems provide adaptive immunity in prokaryotes and promising gene-editing tools from bacteria to humans. Yet, reports diverged on whether some CRISPR systems naturally target DNA or RNA. Here, Samai and colleagues unify the studies, showing that a single type III CRISPR-Cas system cleaves both DNA and RNA targets, independently.

Indexed as

CRISPR-Cas SystemsStaphylococcus epidermidis

Identifiers

PMID26000476
OpenAlexW1603986806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.